Reply to: appropriate dosing of burosumab in tumor-induced osteomalacia

Article Endocrinology & Metabolism

Long-term use of burosumab for the treatment of tumor-induced osteomalacia

C. Crotti et al.

Summary: This case report describes the long-term efficacy and safety profile of burosumab in a TIO patient who had three unsuccessful surgical attempts in tumor removal. Burosumab showed promising results in improving pain, physical performance, and normalizing serum phosphate levels in TIO patients refractory to surgery or not eligible for surgical treatment.

OSTEOPOROSIS INTERNATIONAL (2023)

Add to Collection

Article Endocrinology & Metabolism

Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia

Yasuo Imanishi et al.

Summary: Burosumab (KRN23) shows promising efficacy and tolerability in patients with TIO, effectively increasing serum phosphate levels, improving bone metabolism and pain, especially beneficial for patients who are not eligible for tumor resection.

JOURNAL OF BONE AND MINERAL RESEARCH (2021)

Add to Collection

Article Endocrinology & Metabolism

Tumor induced osteomalacia: A single center experience on 17 patients

C. Crotti et al.

Summary: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by a tumor overproducing FGF-23, leading to bone softening. Surgical treatment is effective with a risk of relapse, and Burosumab shows promise as a therapy.

BONE (2021)

Add to Collection

Article Endocrinology & Metabolism

Burosumab for the Treatment of Tumor-Induced Osteomalacia

Suzanne M. Jan de Beur et al.

Summary: The study demonstrated that burosumab exhibited an acceptable safety profile in adult patients with TIO and was associated with improvements in phosphate metabolism and osteomalacia.

JOURNAL OF BONE AND MINERAL RESEARCH (2021)

Add to Collection

Article Endocrinology & Metabolism